Literature DB >> 16935354

CRF signaling: molecular specificity for drug targeting in the CNS.

Eduardo Arzt1, Florian Holsboer.   

Abstract

Corticotrophin-releasing factor (CRF) is the key mediator of the central nervous system response needed to adapt to stress. If adaptation fails, hypersecretion of CRF continues and produces, via CRF type 1 receptors, symptoms pertaining to cognition, appetite, sleep and anxiety, implicating CRF as a causal factor in affective disorders. Clinical studies with CRF receptor 1 antagonists support a novel pharmacological strategy for treating stress-related disorders. Here we summarize recent information obtained on CRF receptor 1 signaling and propose the concept of a more focused pharmacological intervention based on the signaling pathways involved. Recent findings suggest that CRF activates, via the same CRF receptor 1, different signaling pathways in specific areas of the brain. This intracellular and neuroanatomical signaling specificity will facilitate the search for less pleiotropic antagonists and new chemical compounds that modulate signal transduction in a site-specific manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935354     DOI: 10.1016/j.tips.2006.08.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  29 in total

1.  Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function.

Authors:  Jean-Philippe Fortin; Yuantee Zhu; Charles Choi; Martin Beinborn; Michael N Nitabach; Alan S Kopin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-23       Impact factor: 11.205

2.  MicroRNA 375 mediates the signaling pathway of corticotropin-releasing factor (CRF) regulating pro-opiomelanocortin (POMC) expression by targeting mitogen-activated protein kinase 8.

Authors:  Nan Zhang; Jun-kai Lin; Juan Chen; Xiong-fei Liu; Jia-li Liu; Hao-shu Luo; Yue-qin Li; Sheng Cui
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

3.  Opposing actions of CRF-R1 and CB1 receptors on VTA-GABAergic plasticity following chronic exposure to ethanol.

Authors:  Benjamin A Harlan; Howard C Becker; John J Woodward; Arthur C Riegel
Journal:  Neuropsychopharmacology       Date:  2018-06-09       Impact factor: 7.853

4.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

Review 5.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 6.  Synaptic physiology of central CRH system.

Authors:  Joel P Gallagher; Luis F Orozco-Cabal; Jie Liu; Patricia Shinnick-Gallagher
Journal:  Eur J Pharmacol       Date:  2008-02-01       Impact factor: 4.432

7.  B-Raf and CRHR1 internalization mediate biphasic ERK1/2 activation by CRH in hippocampal HT22 Cells.

Authors:  Juan J Bonfiglio; Carolina Inda; Sergio Senin; Giuseppina Maccarrone; Damián Refojo; Damiana Giacomini; Christoph W Turck; Florian Holsboer; Eduardo Arzt; Susana Silberstein
Journal:  Mol Endocrinol       Date:  2013-01-31

8.  Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats.

Authors:  P-Q Yuan; M Million; S V Wu; J Rivier; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2007-08-10       Impact factor: 3.598

9.  Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal.

Authors:  Alexandre Surget; Yingjie Wang; Samuel Leman; Yadira Ibarguen-Vargas; Nicole Edgar; Guy Griebel; Catherine Belzung; Etienne Sibille
Journal:  Neuropsychopharmacology       Date:  2008-06-04       Impact factor: 7.853

10.  Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice.

Authors:  Cedomir Todorovic; Tessi Sherrin; Matthew Pitts; Cathrin Hippel; Martin Rayner; Joachim Spiess
Journal:  Neuropsychopharmacology       Date:  2008-10-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.